ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test
Executive Summary
After federal agencies invested almost $500m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. It's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
You may also be interested in...
OTC COVID-19 Tests Have Abbott Seeing Continuing Demand For At-Home Diagnostics
“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.
US FDA Recommendations On Developing Serial COVID-19 Tests Could Accelerate OTC Approval
FDA published a supplemental template for molecular and antigen COVID-19 EUA sponsors with products to be used for serial testing, and a fact sheet that screening program organizers can use to pick the right test.
US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm
Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.